Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Fineline Cube Apr 16, 2026
Company Deals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Fineline Cube Apr 16, 2026
Company Deals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

Fineline Cube Apr 16, 2026
Company Deals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Fineline Cube Apr 16, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients

Fineline Cube Apr 17, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Fineline Cube Apr 16, 2026
Company Drug

Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors

Fineline Cube Jun 14, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Deals

Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot

Fineline Cube Jun 14, 2024

Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3...

Company Deals Drug

Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization

Fineline Cube Jun 14, 2024

Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy...

Company Deals Medical Device

Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests

Fineline Cube Jun 14, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has...

Company Drug

Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic

Fineline Cube Jun 14, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...

Company Deals

GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development

Fineline Cube Jun 14, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow...

Company Drug

Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Misses Late-Stage Trial Endpoints

Fineline Cube Jun 14, 2024

Pfizer Inc. (NYSE: PFE) has announced that a late-stage clinical trial for its investigational gene...

Company Drug

AstraZeneca’s Farxiga Receives FDA Approval for Pediatric Type-2 Diabetes Treatment

Fineline Cube Jun 14, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval to AstraZeneca (AZ; NASDAQ:...

Company Drug

Amgen’s Prolia Secures NMPA Approval for Treating Glucocorticoid-Induced Osteoporosis in High-Risk Patients

Fineline Cube Jun 14, 2024

Biopharmaceutical giant Amgen has received marketing approval from China’s National Medical Products Administration (NMPA) for...

Policy / Regulatory

NHSA Seeks Public Input on National Reimbursement Drug List Adjustments

Fineline Cube Jun 14, 2024

The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement...

Company Drug

Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment

Fineline Cube Jun 13, 2024

The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...

Company Deals

Chia Tai Tianqing and China Resource Medicine Commercial Holdings Join Forces for Pharmaceutical Industry Expansion

Fineline Cube Jun 13, 2024

Chia Tai Tianqing, a renowned name in the Chinese healthcare industry, has forged a strategic...

Company Drug

Boehringer Ingelheim’s Survodutide Earns Breakthrough Designation for MASH Treatment in China

Fineline Cube Jun 13, 2024

Boehringer Ingelheim (BI), the German pharmaceutical colossus, has declared that it has been granted Breakthrough...

Company Drug

Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status

Fineline Cube Jun 13, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Meets Primary Endpoint in Severe Alopecia Areata Trial

Fineline Cube Jun 13, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval for Generic Seretide

Fineline Cube Jun 13, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a leading pharmaceutical company based in China,...

Policy / Regulatory

WuXi AppTec and WuXi Bio Shares Rally as US Biosecure Act Excluded from Defense Bill

Fineline Cube Jun 13, 2024

Shares of Chinese Contract Development and Manufacturing Organizations (CDMOs) WuXi AppTec (SHA: 603259) and WuXi...

Company

Haisco Pharmaceutical’s BRAF Inhibitor HSK42360 Gains NMPA Approval for Clinical Trials

Fineline Cube Jun 13, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has...

Company Medical Device

Accuray Wins Chinese Nod for Precision Treatment Planning System, Boosting Regional Expansion

Fineline Cube Jun 13, 2024

U.S. medical device company Accuray Inc. (NASDAQ: ARAY) has announced that it has received market...

Company Deals

Pfizer Forges Partnership with Flagship Pioneering for Novel Obesity Treatments

Fineline Cube Jun 13, 2024

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a...

Posts pagination

1 … 332 333 334 … 652

Recent updates

  • Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio
  • WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients
  • RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal
  • Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio

Company Drug

WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.